A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.

被引：8
|
作者：
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Kaiser Permanente, Cadillac, CA USA
[5] Tricty Hematol Oncol Associates, Mercy Med Ctr, Massilon, OH USA
[6] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[7] Washington Univ, Div Oncol, Dept Med, Sch Med, St Louis, MO USA
[8] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[11] Univ Calif Davis, Sacramento, CA 95817 USA
[12] Yale Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9056
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
    Parra, Edwin R.
    Duose, Dzifa Yawa
    Zhang, Jiexin
    Redman, Mary Weber
    Segura, Rossana Lazcano
    Marques-Piubelli, Mario L.
    Fernandez, Caddie Laberiano
    Zhang, Baili
    Lindsay, James
    Moravec, Radim
    Kannan, Kasthuri
    Luthra, Rajyalakshmi
    Alatrash, Gheath
    Herbst, Roy S.
    Wistuba, Ignacio Ivan
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Lee, J. Jack
    Zhang, Jianjun
    Haymaker, Cara L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] SWOG 0019: A phase II study of gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer (SCLC).
    Akerley, WL
    McCoy, J
    Hesketh, P
    Crowley, J
    Kaye, L
    Gandara, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 666S - 666S
  • [33] A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer
    Bhatia, S
    Hanna, N
    Ansari, R
    Pletcher, W
    Einhorn, L
    Ng, E
    Sandler, A
    LUNG CANCER, 2002, 38 (01) : 73 - 77
  • [34] A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.
    Scagliotti, Giorgio V.
    Govindan, Ramaswamy
    Hurt, Karla
    Chiang, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Phase II study of brigatinib in ROS1-positive non-small cell lung cancer patients previously treated with crizotinib
    Goto, Yasushi
    Niho, Seiji
    Daga, Haruko
    Sakakibara-Konishi, Sakakibara-Konishi
    Tanaka, Hiroshi
    Ohashi, Kadoaki
    Toyozawa, Ryo
    Kotani, Masahiro
    Takahashi, Toshiaki
    Hattori, Yoshihiro
    Morise, Masahiro
    Ikeda, Takaya
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Nomura, Shogo
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2022, 33 : S475 - S475
  • [36] Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer
    Charles M. Haskell
    Evelyn Mendoza
    Katherine M.W. Pisters
    Frank V. Fossella
    Robert A. Figlin
    Investigational New Drugs, 1998, 16 : 81 - 85
  • [37] Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer
    Haskell, CM
    Mendoza, E
    Pisters, KMW
    Fossella, FV
    Figlin, RA
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (01) : 81 - 85
  • [38] Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
    Reckamp, Karen L.
    Redman, Mary Weber
    Dragnev, Konstantin H.
    Villaruz, Liza C.
    Faller, Bryan A.
    Al Baghdadi, Tareq
    Hines, Susan
    Qian, Lu
    Minichiello, Katherine
    Gandara, David R.
    Herbst, Roy S.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer
    Ramalingam, S
    Belani, CP
    Day, R
    Zamboni, BA
    Jacobs, SA
    Jett, JR
    ANNALS OF ONCOLOGY, 2004, 15 (02) : 247 - 251
  • [40] Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
    M. Wada
    M. Yamamoto
    S. Ryuge
    Y. Nagashima
    N. Hayashi
    S. Maki
    S. Otani
    K. Katono
    A. Takakura
    T. Yanaihara
    S. Igawa
    M. Yokoba
    H. Mitsufuji
    M. Kubota
    M. Katagiri
    N. Masuda
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1005 - 1011
12345